Gold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus

Macromol Biosci. 2017 Mar;17(3). doi: 10.1002/mabi.201600359. Epub 2016 Oct 17.

Abstract

The human immunodeficiency virus (HIV) continues to be a global pandemic and there is an urgent need for innovative treatment. Immune cells represent a major target of virus infection, but are also therapeutic targets. Currently, no antiretroviral therapy targets macrophages, which function as portal of entry and as major long-term deposit of HIV. It has been shown before that human macrophages efficiently internalize gold nanoparticles, a fact which might be used to target them with drug-nanoparticle conjugates. Here, the authors use gold nanocarriers to facilitate delivery of stavudine, a widely used antiretroviral drug, to primary human macrophages. Using an ease-of-use coupling method, a striking potentiation of stavudine intake by macrophages using gold nanocarriers is shown. Further, the carriers induce a specific subtype of proinflammatory activation indicative for antiviral activity of macrophages, which suggests promising novel treatment options for HIV.

Keywords: HIV; drug delivery; gold nanoparticles; macrophages; nanocarriers; stavudine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • HIV-1 / pathogenicity
  • Humans
  • Macrophages / drug effects*
  • Macrophages / immunology
  • Macrophages / virology
  • Metal Nanoparticles / administration & dosage*
  • Metal Nanoparticles / chemistry
  • Stavudine / administration & dosage*
  • Stavudine / chemistry

Substances

  • Stavudine